Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05162365 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
A Phase 1 study, sponsored by Innovent Biologics (Suzhou) Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 248
- Enrollment target
NCT05162365: Clinical Trial Phase 1 study, sponsored by Innovent Biologics (Suzhou) Co..
NCT05162365 is a Phase 1 study that was terminated before completion, run by Innovent Biologics (Suzhou) Co.. The registered enrollment target is 248 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (313% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05162365, a Phase 1 study, was terminated before completion, sponsored by Innovent Biologics (Suzhou) Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 248 participants
- Enrollment target
Study Summary
This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19.
Primary Outcome
Any AEs and SAEs occurring during the study
Interventions
- OTHER Placebo
- BIOLOGICAL IBI314
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2022-01-06 |
| Est. Completion | 2022-11-18 |
| Phase | Phase 1 |
Why NCT05162365 stopped before completion
NCT05162365 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (313% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05162365 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05162365 about?
NCT05162365 is a clinical study titled "A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19". This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19.
What is the current status of trial NCT05162365?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 248 participants. The study started on 2022-01-06. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT05162365?
The interventions under investigation include: Placebo (OTHER), IBI314 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05162365?
This trial is sponsored by Innovent Biologics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05162365's enrollment target sits among peer trials
248 185th of 2000 higher than 1,814 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI